Real-World Studies
Pretreatment Antibiotics Linked to Higher Mortality in NSCLC Treated With ICIs
Radfar et alClinical and Translational Oncology

Pretreatment antibiotic exposure has frequently been linked to inferior outcomes in patients undergoing immune checkpoint inhibitor (ICI) therapy; however, whether this phenomenon represents an ICI-specific mechanism or generalized host vulnerability has remained uncertain. To investigate this, researchers utilized the TriNetX Research Network to analyze data from 68,723 adults with non-small cell lung cancer (NSCLC) who initiated ICI therapy between 2015 and 2024. Recent antibiotic exposure was defined as receipt of systemic antibiotics within 30 to 1 days before starting an ICI.
After propensity score matching to balance baseline clinical and treatment characteristics, 17,955 patient pairs were evaluated. Primary endpoints included all-cause mortality at 90 and 365 days. Overall, 19,080 of the 68,723 patients had recent antibiotic exposure. Recent exposure was associated with higher mortality at 90 days (17.7% vs 13.7%; HR 1.34, 95% CI 1.27 to 1.41; P < 0.001) and 365 days (43.0% vs 37.2%; HR 1.23, 95% CI 1.19 to 1.27; P < 0.001).
Sensitivity analyses incorporated landmarking, remote exposure assessments, infection stratification, and a non-ICI comparator cohort. The mortality association attenuated after excluding early deaths, and remote antibiotic exposure did not reproduce the adverse effect. Furthermore, the 90-day association was similar between ICI and non-ICI cohorts, indicating that early excess mortality is driven primarily by underlying clinical vulnerability. A modestly stronger association was observed with ICI therapy at 365 days, which the authors noted is hypothesis-generating.
Key Takeaways
- In a propensity-matched analysis of adults with NSCLC, recent antibiotic exposure within 30 days prior to ICI initiation was associated with increased all-cause mortality at 90 days (17.7% vs 13.7%; HR 1.34, 95% CI 1.27 to 1.41; P < 0.001) and at 365 days (43.0% vs 37.2%; HR 1.23, 95% CI 1.19 to 1.27; P < 0.001).
- Mortality associations attenuated after excluding early deaths and were comparable between ICI and non-ICI cohorts at 90 days, indicating that early excess mortality predominantly reflects underlying clinical vulnerability rather than an ICI-specific effect, with a modestly stronger association emerging for ICI therapy at 365 days.
Read the original sourceClinical and Translational Oncology
